Rittberg, R.; Leung, B.; Shokoohi, A.; Pender, A.; Wong, S.; Al-Hashami, Z.; Wang, Y.; Ho, C.
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Curr. Oncol. 2023, 30, 5299-5308.
https://doi.org/10.3390/curroncol30060402
AMA Style
Rittberg R, Leung B, Shokoohi A, Pender A, Wong S, Al-Hashami Z, Wang Y, Ho C.
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current Oncology. 2023; 30(6):5299-5308.
https://doi.org/10.3390/curroncol30060402
Chicago/Turabian Style
Rittberg, Rebekah, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, and Cheryl Ho.
2023. "Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy" Current Oncology 30, no. 6: 5299-5308.
https://doi.org/10.3390/curroncol30060402
APA Style
Rittberg, R., Leung, B., Shokoohi, A., Pender, A., Wong, S., Al-Hashami, Z., Wang, Y., & Ho, C.
(2023). Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current Oncology, 30(6), 5299-5308.
https://doi.org/10.3390/curroncol30060402
